Context
Founded by Philippe Genne in 1995, Oncodesign has developed an hybrid business model including pre-clinical CRO services and its own pipeline of therapeutic and diagnostic projects.
Following a reorganisation of its operations in distinct business units in 2020, Oncodesign decided to split into two separate listed companies with distinct business models. The separation will be executed through a spin-off of the Biotech and AI activities in a new company named Oncodesign Precision Medicine that will be listed on Euronext Growth.
Elyan Partners together with Philippe Genne and the current management team announced in parallel its intention to acquire after split a majority stake in the group's pre clinical CRO activities followed by a tender offer for the remaining capital.
About Oncodesign
Founded by Philippe Genne in 1995, Oncodesign has developed a unique technology platform in precision medicine for the discovery of new therapies against cancer and serious illnesses. Its hybrid business model includes three business units: Pre-clinical CRO Services, its own pipeline of therapeutic/diagnostic projects and AI services for drug discovery.
Oncodesign has more than 1,000 clients/partners across 23 countries, including the 15 biggest pharma companies. The Company invests in 3 internal Drug Discovery projects on new kinase inhibitors and leads 2 international scientific and technological partnerships.
Oncodesign has been listed on Euronext Growth since 2014 and will be split in two different listed entities as part of this transaction: Oncodesign focused on CRO services and Oncodesign Precision Medicine owning the Biotech and AI activities.
About Elyan Partners
Elyan Partners is the exclusive advisor to ERES funds (Edmond de Rothschild Equity Strategies). ERES invests in midcap companies in Europe or North America, mainly in four verticals: the biotech ecosystem, e-commerce, financial services and new consumer habits.
Edmond de Rothschild Private Equity is an independent company within Edmond de Rothschild Asset Management and manages more than CHF 3.4bn of AuM. Through its entreprenarial mindset and conviction-driven investments, Edmond de Rothschild Private Equity builds and deploys differentiated investment strategies for sustainable solutions to current socio-environmental issues. Founded in 1953, the Group manages close to CHF 178bn AuM as of 31 December 2021, with 2,500 people across 32 offices.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Sole Financial Advisor to Oncodesign on the sale of its CRO activities to Elyan Partners for €100m and the concomitant spin-off of its Biotech/AI activities
Bryan, Garnier & Co acts as Sole Financial Advisor to Oncodesign in the sale of its pre clinical CRO activities to Elyan Partners and the separate listing of Oncodesign Precision Medicine, the group’s biotech and AI activities.
We have partnered with Oncodesign and its team over the past several years to pave the way for such a complex transaction and to make it possible at the right time to maximise value for shareholders. This transaction is a great example of our sector, M&A and public expertises being leveraged and combined together as well as the absolute commitment of the Bryan, Garnier & Co teams which made it happen in a very condensed timeline.
This deal illustrates our passion to advise healthcare founders and entrepreuneurs in decisive moments for their company and further strengthens Bryan, Garnier & Co position as the leading advisor for healthcare mid cap growth companies across Europe.
Share